MiniMed to begin trading on Nasdaq Global Select Market

Key Takeaways:

• MiniMed now trades on the Nasdaq Global Select Market under “MMED.”
• The IPO was oversubscribed, indicating strong investor demand.
• This debut ranks as the second largest IPO in MedTech history.
• MiniMed originated as a spin-off from Medtronic.
• Geoff Martha describes the launch as an “exciting milestone” for both companies.

A Landmark Launch

MiniMed Group, Inc. made its public-market appearance on March 6, 2026, trading on the Nasdaq Global Select Market under the ticker symbol “MMED.” The company, established as part of a spin-off by Medtronic plc, quickly drew attention for its oversubscribed offering that landed it the distinction of being the second largest IPO in MedTech history.

Market Significance

Investor response to the MiniMed IPO has been robust, even in the midst of geopolitical uncertainties shaping today’s economic climate. The oversized demand for the offering underscores the healthcare sector’s sustained appeal and the potential investors see in MiniMed’s innovative technology.

Background and Leadership Outlook

Medtronic chairman and chief executive officer Geoff Martha offered a clear endorsement of MiniMed’s new path: “Today marks an exciting milestone for both MiniMed and Medtronic. Despite a challenging market backdrop shaped by geopolitical uncertainty, the teams successfully executed an oversubscribed offering and the second largest IPO in Medtech history.” He added that establishing MiniMed as a standalone entity positions the company “to operate with greater agility over the long term.”

Strategic Growth Potential

Martha’s comments highlight the reasoning behind separating MiniMed from Medtronic: streamlined operations, heightened adaptability, and renewed focus on delivering advanced healthcare solutions. With its own leadership and dedicated resources, MiniMed is poised to grow with a singular vision, drawing on Medtronic’s legacy while forging its own path.

For more details on MiniMed’s market debut and additional commentary, see the full story available on Benzinga.com.